Skip to content
DataLookout
Menu

NCT04676477

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 18 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 63 words Show 4 more changesShow less
    • Study completion pushed from Apr 30, 2027 to Dec 14, 2027
    • Secondary endpoints: details revised at 3 of 13 entries
    • Collaborators: details revised at 1 of 2 entries
    • Study description expanded, about 2 words
  2. Notable Eligibility criteria revised
    • Enrollment target: estimated 280 to confirmed 246
    • Primary completion date changed from estimate of Jun 1, 2025 to Jan 31, 2025
    • Study completion date: Feb 1, 2026 to Apr 30, 2027
    v19
  3. Notable Eligibility criteria revised
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 31 of 31 sites
    v18
  4. Notable Eligibility criteria revisedv16
  5. Notable Eligibility criteria expanded, about 64 words
    • Secondary endpoints: details revised at 3 of 13 entries
    • Site details revised at 1 of 31 sites
    • Collaborators expanded, about 6 words
    v15
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Site details revised at 1 of 31 sitesv14
  2. Minor Site details revised at 4 of 31 sitesv13
  3. Minor Primary completion date: Jun 2025 to Jun 1, 2025
    • Study completion date: Feb 2026 to Feb 1, 2026
    • Site details revised at 5 of 31 sites
    v12
  4. Minor Study sites: 16 to 31v11
  5. Notable Primary completion date: Jan 2024 to Jun 2025v10 Show 10 more changesShow less
    • Eligibility criteria expanded, about 139 words
    • Primary endpoints: 3 to 2
    • Enrollment target: 252 to 280
    • Study sites: 15 to 16
    • Study completion date: Jan 2024 to Feb 2026
    • Interventions: Osimertinib (Drug), Osimertinib (Drug), Osimertinib (Drug), Patritumab deruxtecan (Drug), Patritumab deruxtecan (Drug), Patritumab… to HER3-DXd (Drug), HER3-DXd (Drug), HER3-DXd (Drug), HER3-DXd (Drug), Osimertinib (Drug), Osimertinib (Drug), Osimertinib (Drug)
    • Secondary endpoints: 12 to 13
    • Study arms: 4 to 6
    • Study description shortened, about 1 word
    • Study title expanded, about 2 words
  6. Minor Study sites: 14 to 15v9
  7. Minor Study sites: 11 to 14v8
  8. Minor Study sites: 7 to 11v7
  9. Notable Eligibility criteria expanded, about 27 words
    • Site details revised at 1 of 7 sites
    v5
  10. Minor Study sites: 5 to 7v4
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2021 to Jun 11, 2021
    • Site details revised at 5 of 5 sites
    v3
  12. Notable Start date: Jan 2021 to Apr 2021
    • Eligibility criteria expanded, about 76 words
    • Study sites revised (5)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose Escalation: Incidence of Dose-limiting Toxicities (DLT), Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
Timeframe: From signing of informed consent form up to 40 days (+7 days) after the last dose of study drugs, up to approximately 9 months
Second-line Dose Expansion and First-line Dose Expansion: Objective Response Rate (ORR)
Timeframe: From start of study treatment until date of documented disease progression or other protocol-defined reason for discontinuation from the study (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 18 months

Secondary (13)

Dose Escalation: Objective Response Rate (ORR)
Second-line Dose Expansion and First-line Dose Expansion: Objective Response Rate (ORR)
Dose Escalation, Second-line Dose Expansion, and First-Line Dose Expansion: Duration of Response (DoR)
Second-line Dose Expansion: Clinical Benefit Rate (CBR)
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Disease Control Rate (DCR)
Show 8 moreShow less
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Time to Response (TTR)
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Progression-free Survival (PFS)
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Overall Survival (OS)
Second-line Dose Expansion and First-line Dose Expansion: Incidence of Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Proportion of Participants Who Have Treatment-emergent ADA
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Pharmacokinetic Parameter Maximum Concentration (Cmax)
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)

Arms and interventions

Dose Escalation: HER3-DXd + osimertinibExperimental

Participants in the Dose Escalation phase will receive HER3-DXd IV Q3W + osimertinib PO once daily. The dose of HER3-DXd in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.

Second-line Dose Expansion: HER3-DXd + osimertinib (RCD)Experimental

Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd + osimertinib at the RCD

Second-line Dose Expansion: HER3-DXdExperimental

Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W

First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 3; RCD)Experimental

If the RCD includes an osimertinib dose of 80 mg PO once daily, then participants will receive treatment with HER3-DXd and osimertinib at the RCD

First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4a)Experimental

Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.

First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4b)Experimental

Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 4.8 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.

Drugs: HER3-DXd, Osimertinib

Sites

31 sites in 4 countries

United States 13, Japan 10, South Korea 4, Taiwan 4